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Introduction: Polyneuropathy (PN) complaints are common, prompting many referrals
for neurologic evaluation. To improve access of PN care in distant community clinics,
we developed a telemedicine service (patient-clinician interactions using real-time
videoconference technology) for PN. The primary goal of this study was to construct a
remote exam for PN that is feasible, reliable, and concordant with in-person assessments
for use in our tele-PN clinics.
Methods: To construct the VA Neuropathy Scale (VANS), we searched the literature
for existing, validated PN assessments. From these assessments, we selected a
parsimonious set of exam elements based on literature-reported sensitivity and specificity
of PN detection, with modifications as necessary for our teleneurology setting (i.e., a
technician examination under the direction of a neurologist). We recruited 28 participants
with varying degrees of PN to undergo VANS testing under 5 scenarios. The 5 scenarios
differed by mode of VANS grading (in-person vs. telemedicine) and by the in-person
examiner type (neurologist vs. technician) in telemedicine scenarios. We analyzed
concordance between the VANS and a person’s medical chart-derived PN status by
modeling the receiver operating characteristic (ROC) curve. We analyzed reliability of the
VANS by mixed effects regression and computing the intraclass correlation coefficient
(ICC) of scores across the 5 scenarios.
Results: The VA Neuropathy Scale (VANS) tests balance, gait, reflexes, foot inspection,
vibration, and pinprick. Possible scores range from 0 to 50 (worst). From the ROC curve,
a cutoff of >2 points on the VANS sets the sensitivity and specificity of detecting PN at 98
and 91%, respectively. There is a small (1.3 points) but statistically significant difference in
VANS scoring between in-person and telemedicine grading scenarios. For telemedicine
grading scenarios, there is no difference in VANS scores between neurologist and
technician examinations. The ICC is 0.89 across all scenarios.
Discussion: The VANS, informed by existing PN instruments, is a promising clinical
assessment tool for diagnosing and monitoring the severity of PN in telemedicine
settings. This pilot study indicates acceptable concordance and reliability of the VANS
with in-person examinations.
Keywords: neuropathy, telemedicine, reliability, neuromuscular, examination
Wilson et al. VANS Reliability
INTRODUCTION
Polyneuropathy (PN) complaints are common, prompting many
referrals for neurologic evaluation. In our healthcare system,
many of these referrals come from distant community clinics that
do not have neurologists on site and serve a disproportionate
number of adults for whom access to urban referral centers can
be particularly difficult (1). To improve access and convenience of
PN care for populations served in community clinics, we piloted
a telemedicine service (patient-clinician interactions using real-
time videoconference technology) for PN.
Telemedicine has expanded the ability of specialists to evaluate
and treat chronic conditions remotely (2). Within the field of
neurology, telemedicine (or teleneurology) has been employed
successfully in chronic conditions principally assessed by history
or visual inspection, such as dementia, epilepsy, and movement
disorders (3, 4). However, teleneurology for neuromuscular
disorders, such as PN, has not been trialed extensively, given
the need for “hands-on” physical exam elements (e.g., eliciting
reflexes, testing sensation) to assist with diagnosis and staging
of the disease (5). Thus, the primary goal of this study was
to develop a remote exam for PN that was feasible, reliable,
and concordant with in-person assessments for use in our tele-
PN clinics.
Our exam, the VA Neuropathy Scale (VANS), is a
standardized PN assessment that resembles a focused-in
person neuromuscular exam. The VANS was informed by
existing, validated PN assessments and was modified for a
clinical teleneurology setting (i.e., a technician examination
under the direction of a neurologist). This article describes
the development and pilot testing of the VANS for remote PN
assessment and describes the VANS psychometric properties for
this purpose.
METHODS
Development of the VA Neuropathy Scale
(VANS)
We searched the literature for clinical neuropathy exams
using the PubMed search terms of (“polyneuropathy” OR
“polyneuropathies” OR “neuropathy” OR “neuropathies”) AND
(“scale” OR “score” OR “exam” OR “assessment”) AND
(“sensitivity” OR “sensitive” OR “specificity” OR “specific” OR
“reliability” OR “reliable” OR “validity” OR “valid”) in the title
or abstract. The search resulted in 385 articles. We (AMW,
NIJ) scanned the titles and abstracts to identify neuropathy
exam scales. We excluded symptom checklists or exams
requiring specialized quantitative tools. The search resulted in
10 PN assessments, which we deconstructed into discrete exam
elements. We evaluated exam elements for inclusion into the
VANS based on literature-reported sensitivity and specificity of
Abbreviations: AUC, area under the curve; CI, confidence interval; GLA
VA, Greater Los Angeles Veterans’ Affairs Healthcare System; ICC, intraclass
correlation coefficient; MD, neurologist (medical doctor); NCS, nerve conduction
study; PN, polyneuropathy; ROC, receiver operating characteristic curve; TCT,
telehealth care technician; TeleMD, tele-neurologist (medical doctor); VANS, VA
Neuropathy Scale.
PN detection as well as our team’s judgement of exam element
difficulty within the telemedicine setting.We assessed difficulty as
challenges to the examiner’s technique and/or to the neurologist’s
observation of the exam element. We selected a parsimonious set
of exam elements, with modifications as necessary, to form the
VA Neuropathy Scale (VANS).
Concordance and Reliability Testing of the
VA Neuropathy Scale (VANS)
This study was approved as a quality improvement activity by the
Greater Los Angeles Veterans’ Affairs Healthcare System (GLA
VA) IRB. The need for written informed consent was waived by
the IRB subcommittee that approved the study. Informed verbal
consent was obtained from all participants.
Our primary outcome for this pilot was to determine the
agreement of VANS scores via intraclass correlation coefficient
(ICC) across 5 different scenarios (see Table 1). The scenarios
differed on (1) whether the mode of VANS grading was in-
person vs. remote (i.e., telemedicine), and (2) for remote grading
scenarios, whether the in-person examiner was a board-certified
neurologist vs. a telehealth care technician (TCT, a medical
assistant or licensed vocational nurse without neurological
exam experience).
Aiming to test the VANS across a spectrum of patients, we
followed a purposive sampling technique to enroll Veterans
from our neurology clinic with the following 3 PN disease
categories based on their recent neurologic note in the medical
record: no PN, PN without falls (PN-F), and PN with falls
(PN+F). We defined no PN as an absence of the entire set
of neuropathic symptoms, neuropathic signs, and neuropathic
diagnosis. To be defined as PN, patients must have met the
“Probable Clinical PN” criteria from the Toronto Expert Panel’s
definition (“a combination of symptoms and signs of distal
sensorimotor polyneuropathy with any two or more of the
following: neuropathic symptoms, decreased distal sensation, or
unequivocally decreased or absent ankle reflexes”) (6, 7). We
segmented the PN group into those with or without falls within
the last 3 months as a crude indicator of functional severity.
TABLE 1 | The 5 scenarios (A-E) for VANS reliability testing.
Scenario In-person examiner In-person grader Remote grader
A MD#1 MD#1
B MD#2 MD#2
C MD#1 or MD#2 TeleMD#3 or TeleMD#4
D TCT#1 TeleMD#3 or TeleMD#4
E TCT#2 TeleMD#3 or TeleMD#4
The table describes each scenario by listing the in-person examiner, the in-person
grader (when applicable), and the remote grader (when applicable). In scenario A and
B, participants are examined and graded by an in-person neurologist, similar to a typical
face-to-face encounter. In scenario C, participants are examined by one of the in-person
neurologists, but the grading is done by one of the remote tele-neurologists. In scenarios
D and E, participants are examined in-person by a telehealth care technician (TCT), but
the grading is done by one of the remote tele-neurologists. MD = neurologist; TeleMD =
tele-neurologist; TCT = telehealth care technician.
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FIGURE 1 | VANS study recruitment algorithm. PN, polyneuropathy.
We screened the medical charts of the 100 Veterans from
the GLA VA region who had been referred to neurology
for neuropathic complaints since January 2016 and who
subsequently had an encounter diagnosis of PN from the
neurologist. We also screened the charts of 20 Veterans without
neuropathic complaints who had a recent neurology visit.
Documentationwas sufficient to place all 120 individuals into one
of the 3 defined PN categories.
With a desired sample size of 32 patients, our study was
powered to detect a 95% confidence interval (CI) half-width of
0.15 from our hypothesized ICC of 0.7 across the 5 scenarios
(8). We contacted all 120 Veterans in an attempt to enroll
40 participants, with at least 10 individuals in each of the 3
PN categories. The slightly larger enrollment was to protect
from participant attrition. Ultimately, 36 Veterans agreed to
participate. The recruitment algorithm for reliability testing of
the VANS is illustrated in Figure 1.
After verbal informed consent was obtained from the 36
participants, they were asked to come to the West Los Angeles
VA facility on a single day to have VANS testing under 5
scenarios (see Table 1). Twenty-eight of the 36 Veterans arrived
for reliability testing. Four individuals completed only 4 exams
rather than 5 exams due to scheduling conflicts.
We block randomized participants 1:1 to the two remote
neurologists (TeleMD#3 or TeleMD#4) in each scenario of C,
D, and E. For scenario C, we additionally block randomized
participants 1:1 to the two in-person neurologists (MD#1 or
MD#2). The order of testing for each patient was randomized to
account for possible order effects in which participant behavior
or provider performance might be influenced by prior exams.
All neurologists and technicians were blinded to the patients’
medical record-derived PN category. Schedules were arranged
such that all participants could complete the 5 exams within
3 h. The 2 in-person neurologists and 2 technicians had received
15min of basic exam technique training and 5 mock patient
encounters (∼30min total) to learn the exam.
For analysis, we provide the descriptive statistics of the
VANS scores for the cohort and by PN disease category (no
PN, PN-F, PN+F). Regression analysis on clustered data was
performed to demonstrate the relationship between PN category
and VANS scores. We depict the non-parametric receiver
operating characteristic (ROC) curve of the VANS and calculate
the area under the curve (AUC) to illustrate the concordance
between the medical record-derived binary PN category (no PN
vs. PN with or without falls) and a VANS PN indicator. An
AUC of 0.5 indicates chance agreement between the medical-
record disease state and the VANS PN indicator while an AUC
of 1 indicates perfect agreement. We empirically identify the
“statistically best” cutoff for the VANS score to determine the
presence of PN by both the Liu and Youden methods (9). Based
on this cutoff, we calculated the sensitivity, specificity, positive
predictive value, and negative predictive value of the VANS for
this purposive sample.
For interrater reliability, we computed the absolute agreement,
individual intraclass correlation coefficient (ICC) across the 5
scenarios using a mixed effects model. In the model, participants
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TABLE 2 | Overview of existing polyneuropathy assessments.
Item Revised NDS MNSI MDNS TNS NIS-LL DNE TCSS UENS mTCNS ENS VANS
Pin sensation At toe: [0–1] At toe:
0 = painful
2 = not painful
[0–4] region At toe: [0–2] At toe finger:
[0–2]
At toe: [0–1] [0–2] in each of
6 leg regions
[0–3] region At toe: [0–2] [0–2] in each of 6
leg 2 hand
regions
Temperature At toe: [0–1] using
cold tuning fork
At toe: [0–1] [0–3] region At foot: [0–2]
using cold
thermal disks
Position sense At toe: [0–2] At toe: [0–2] At toe: [0–1] At toe: [0–2] [0–3] region
Vibration At toe: [0–1] At toe: [0–2] 0.5 At toe: [0–2] [0–4] region At toe: [0–2]
using 165Hz
fork
At toe: [0–2] At toe: [0–1] At toe: [0–2] [0–3] region At toe: [0–2] At toe: [0–2]
At knee: [0–2]
Light touch At toe: [0–2]
with SW
monofilament
At toe: [0–2] At toe: [0–2] At toe: [0–1] [0–3] region At toe: [0–2]
with SW
monofilament
Great toe
extension
[0–3] severity [0–4] severity [0–4] severity [0 or 2]
Ankle reflexes [0–2] [0–2] *0.5 [0–2] [0–2] [0–2] [0–2] [0–2] [0–2] [0–2]
Knee reflexes [0–2] [0–2], counted
only if ankle
reflexes absent
[0–2] [0–2] [0–1]
Other Foot visual:
[0–1], additional
point for ulcer
Strength—see
note 1
Reflex—see
note 2
Strength—see
note 3
Strength—see
note 4
Allodynia in
toes/feet: [0–1]
Foot visual: [0–1]
Romberg: [0–1]
Gait - see note 5
References Young et al. (10) Feldman et al.
(11)
Feldman et al.
(11)
Chaudhry et al.
(12)
Bril (13) Meijer et al. (14) Bril and Perkins
(15)
Singleton et al.
(16)
Bril et al. (17) Zilliox et al. (18) Present Study
The table summarizes the PN exam items and scoring for each of the 10 PN assessments. The VA Neuropathy Scale (VANS) is listed in the last column for comparison. The 10 assessments are as follows: Revised Neuropathy Disability
Score (NDS); Michigan Neuropathy Screening Instrument (MNSI); Michigan Diabetic Neuropathy Score (MDNS); Total Neuropathy Score (TNS); Neuropathy Impairment Score-Lower Limb (NIS-LL); Diabetic Neuropathy Examination
(DNE); Toronto Classification Scoring System (TCSS); Utah Early Neuropathy Score (UENS); modified Toronto Classification Neuropathy Score (mTCNS); Early Neuropathy Score (ENS). SW, Semmes Weinstein monofilament.
Grading Legend.
[0 or 2]: 0 = normal, 2 = weak. [0–1]: 0 = normal, 1 = abnormal. [0–2]: 0 = normal, 1 = reduced, 2 = absent. [0–3] region: 0 = normal, 1 = reduced at toes, 2 = reduced to ankle, 3 = reduced above ankles. [0–3] severity: 0 = normal,
1 = mild to moderate weakness, 2 = severe weakness, 3 = no strength. [0–4] region: 0 = normal, 1 = reduced in fingers/toes, 2 = reduced to ankle/wrist, 3 = reduced to knee/elbow, 4 = reduced beyond knee/elbow. [0–4] severity: 0
= normal, 1 = mildly weak, 2 = moderately weak, 3 = severely weak, 4 = paralysis. Note 1: Finger spread and ankle dorsiflexion rated [0–3] severity. Note 2: Biceps and triceps reflexes rated [0–2]. Note 3: Strength rated [0–4] severity,
including partial points. Muscles tested includes hip flexion, hip extension, knee flexion, knee extension, ankle dorsiflexion, ankle plantar flexion, toe extension, toe flexion. Note 4: Quadriceps and tibialis anterior tested with score 0 =
normal, 1 = at least antigravity, 2 = weaker than antigravity. Note 5: Gait is tested by casual, heel, and tandem walk with score rated [0–1].
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TABLE 3 | Summary of PN exam element sensitivity, specificity, and telemedicine difficulty.
Item Sensitivity Specificity Frequency used Difficulty Difficulty comment Other comments
Pin sensation 72% 91% 9/10 -
Temperature 60% 89% 4/10 -
Position sense 36% 98% 5/10 + Observability Modified to Romberg
Vibration 73% 77% 10/10 -
Light touch 45% 96% 6/10 -
Great toe extension 44% ? 4/10 + Technique Modified to heel walk
Ankle reflexes 74% 62% 9/10 ++ Technique, observability
Knee reflexes 52% 96% 4/10 + Technique
Foot inspection ? ? 1/10 -
Gait 43% ? 0/10 - Modified to casual and tandem gait
The table describes the sensitivity and specificity of exam elements in Abraham el al.’s cohort of 312 PN patients (19). The fourth column indicates the frequency of an item’s use out
of the 10 PN assessments listed in Table 1. The fifth column is our team’s assessment of the difficulty of exam element use in the telemedicine setting, with the reason for each “+”
challenge listed in the sixth column. An element gets a “+” for either challenges related to mastery of the exam technique by the examiner and/or to the remote neurologist observing
(and correcting if need be) the exam technique or response. The final column illustrates how we modified the VANS as possible to include desired elements. VANS, VA Neuropathy Scale.
were the random effect with scenario as the fixed effect. After
computing the mixed effects models, contrasts of fixed effects
parameters were calculated to test differences in scores between
our “gold standard” in-person examinations (scenarios A and
B) and teleneurology examinations (scenarios C, D, and E). For
intra-rater reliability, we calculated Spearman correlations and
performed Wilcoxon signed-rank test for VANS scoring when
either the in-person neurologist repeated the exam on the same
person (scenario A or B with C) or the remote neurologist
repeated the exam (scenario C with D or E OR scenario D with
E). Analysis was performed using STATA v15.
RESULTS
Development of the VA Neuropathy Scale
(VANS)
The development of the VANS was informed by the following
list of validated assessments that screen for and monitor
PN: the Neuropathy Disability Score (NDS); the Michigan
Neuropathy Screening Instrument (MNSI); the Michigan
Diabetic Neuropathy Score (MDNS); the Total Neuropathy
Score (TNS); the Neuropathy Impairment Score-Lower Limb
(NIS-LL); the Diabetic Neuropathy Examination (DNE); the
Toronto Classification Scoring System (TCSS); the Utah Early
Neuropathy Score (UENS); the modified Toronto Classification
Neuropathy Score (mTCNS); and the Early Neuropathy Score
(ENS) (10–18). Table 2 summarizes each assessment’s exam
elements, most of which were common to multiple assessments.
The number of exam elements per assessment ranged from 3 to
8. Briefer assessments (e.g., MNSI, ENS) generally coincided with
a purpose of clinical use/screening, while more comprehensive
assessments (e.g., MNDS, NIS-LL) were typically utilized in
monitoring PN changes in clinical trials. This was most apparent
in the domain of reflex and strength testing. Assessments did vary
in the weighting of exam elements; some assessments assigned
more points to severe distal deficits of particular exam elements
(e.g., MDNS), while others assigned more points to the spread of
deficits. The TCSS is an example of spread to different fiber types
as it provides superficial coverage for distal motor, large-fiber, and
small-fiber neuropathy. The mTCNS is an example of centripetal
spread of sensory deficits to more proximal body regions. The
mTCNS does not include reflex or strength testing at all. Unique
to the UENS, pinprick sensation was tested over 6 leg regions, a
feature that made it more sensitive to small-fiber neuropathy.
Table 3 provides further details about the common exam
elements: the literature reported sensitivity and specificity of PN
detection, frequency of use across the 10 PN assessments, and
our team’s anecdotal experience and clinical judgement of the
telemedicine difficulty of these exam elements. From the work
of Abraham et al. in a cohort of 312 patients with PN, the most
sensitive exam elements for PN are ankle reflexes (74%), vibration
(73%), and pinprick sensation (72%) (19). The most specific
elements for PN are position sense at toes (98%), light touch at
toes (96%), and knee reflexes (96%) (19). Though not universally
included in each assessment, the most frequently tested exam
elements were vibration (10/10), pin sensation (9/10), and ankle
reflexes (9/10). Items such as temperature sensation, position
sense, light touch, strength testing, gait, and feet inspection were
also noted. From our experience, the exam elements that require
examiner practice beyond a 20-min training session are strength
testing and reflexes. Exam elements that are difficult to observe
remotely, and to redirect if necessary, are position sense at toes
and ankle reflexes.
Based on a review of the above factors, we developed the
VANS (Figure 2). We selected elements to optimize clinical
utility, sensitivity and specificity of PN detection, monitoring
of disease progression, and reliability. The VANS thus tests 6
exam elements: balance, gait, foot inspection, vibration, knee
reflexes, and pinprick testing. The VANS scores can range from
0 (best) to 50 (worst) with examiners assigning points for
abnormalities deemed attributable to distal symmetric PN. For
balance, the Romberg test is performed with feet together, eyes
closed for 20 s (20). Casual gait, walking on heels, and tandem
gait (with feet touching in heel-to-toe orientation) are assessed
with wide-based gait, steppage gait, or inability to perform the
gait as abnormal. Knee reflexes are tested with a Queen Square
hammer and are abnormal if depressed or absent. Inspection
Frontiers in Neurology | www.frontiersin.org 5 November 2019 | Volume 10 | Article 1050
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The VA Neuropathy Scale
Romberg
0=normal
1=step off
Casual Gait
0=normal
1=abnormal
Heel Walk
0=normal
1=abnormal
Tandem Walk
0=normal
1=abnormal
Left Knee Reflex
0=normal or brisk
1=absent or depressed
Right Knee Reflex
0=normal or brisk
1=absent or depressed
Left Foot Inspection
0=normal
2=ulcers, skin fissures
Right Foot Inspection
0=normal
2=ulcers, skin fissures
Left Toe Vibration
0=normal
1=decreased
2=absent
Right Toe Vibration
0=normal
1=decreased
2=absent
Left Knee Vibration
0=normal
1=decreased
2=absent
Right Knee Vibration
0=normal
1=decreased
2=absent
Segments for pin sensation reporting
Left pinprick
0=normal
1=reduced
2=absent
Right pinprick
0=normal
1=reduced
2=absent
Region8
Region7
Region6
Region5
Region4
Region3
Region2
Region1
TOTAL SCORE------------------------------------------------------
FIGURE 2 | The VA neuropathy scale.
of feet is considered abnormal if there is skin breakdown, such
as fissures or ulcers (dry skin, skin discoloration, or change in
hair pattern does not count). Vibration using a 128Hz Rydel-
Seiffer tuning fork at the toe and knee is performed, with values
4 or below considered abnormal (21). If a patient does not
feel any vibration on maximal stimulation, the assessor assigns
2 points. Pinprick sensation using NeurotipsTM is performed
by first demonstrating “normal” sharp on the forearm or, if
necessary, the cheek. Participants can say whether the pinprick
is “normal sharp,” “somewhat sharp,” or “not sharp at all” as
the examiner moves up centripetally from the big toe or middle
finger in roughly 2-cm increments until a level of change can
be identified. Regions are scored based on the worst response
for that region. The VANS scoring rubric is also seen on the
rightmost column of Table 2 for ease of comparison to existing
PN assessments.
Concordance and Reliability Testing of the
VA Neuropathy Scale (VANS)
Of the 28 participants, 24 (86%) were male and 15 (54%)
were white. The average age was 64 years with a range of
26 to 85 years. The etiologies for PN in the 19 affected
participants were as follows: diabetes (n = 5), pre-diabetes
(n = 3), idiopathic (n = 3), alcohol abuse (n = 3),
monoclonal gammopathy of unclear significance (n = 2),
chemotherapy-induced (n = 2), and hereditary sensory motor
neuropathy (n= 1).
VANS scores ranged from 0 to 28, with a mean of 8.1
and median of 6. Figure 3 shows the distribution of VANS
scores for the cohort and by PN disease category. The average
VANS scores by PN disease category were 0.95, 8.66, and
16.53 for no PN, PN-F, and PN+F, respectively. There was
a significant association between VANS score and PN disease
Frontiers in Neurology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 1050
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FIGURE 3 | The distribution of VANS scores. (A) VANS scores for the entire cohort ranged from 0 to 28 with a median of 6. The mean was 8.1 with a standard
deviation (SD) of 7.3. (B) There is a significant relationship between VANS score and PN status (F2,27 = 70.16; P-value < 0.0001). The average (SD) score of no PN,
PN-F, and PN+F is 1.0 (1.5), 8.7 (5.3), and 16.5 (4.7) points, respectively. VANS, VA Neuropathy Scale; PN, polyneuropathy; PN-F, polyneuropathy without falls;
PN+F, polyneuropathy with falls.
FIGURE 4 | The Receiver Operating Characteristic (ROC) curve. The
non-parametric ROC curve depicts the tradeoff of sensitivity and specificity of
the VANS identifying polyneuropathy at different cutoff values of VANS scores.
The area under the curve (AUC) is 0.98 (95% CI 0.95 to 0.99), with an AUC of
1 indicating perfect agreement between the VANS PN indicator and the actual
disease status. The optimal cutoff by both Liu and Youden methods is 2
(meaning VANS scores >2 indicates the presence of PN). VANS, VA
Neuropathy Scale; CI, confidence interval; PN, polyneuropathy.
category (F2,27 = 70.16; P-value < 0.0001). The ROC curve
is shown in Figure 4 and has an area under the curve (AUC)
of 0.98 (95% CI 0.95 to 0.99). The “statistically best” cutoff
for defining PN by the Liu or Youden criteria was >2 points.
The sensitivity and specificity of identifying PN with a score
>2 was 98 and 91%, respectively. In this sample, the positive
predictive value was 96%, and the negative predictive value was
95%. These results did not materially change when excluding
those Veterans in the more impaired PN+F category (n =
7 participants).
TABLE 4 | Interrater reliability of the VANS.
Scenarios ICC (95% CI)
Scenarios A–E: All scenarios 0.89 (0.81–0.94)
Scenarios A–B: Only in-person scenarios 0.91 (0.81–0.95)
Scenarios C–E: Only telemedicine scenarios 0.86 (0.75–0.92)
Scenarios D–E: Only TCT telemedicine scenarios 0.85 (0.71–0.93)
Interrater reliability of the VANS is demonstrated by the intraclass correlation coefficients
(ICCs) of the participants’ VANS scores across different scenarios (see Table 1 for
scenario descriptions). An ICC of 1 is perfect agreement in scores. The first column
mentions the exam scenarios to be compared. The second column shows the ICC point
estimates and 95% confidence interval for the specified scenario based on the mixed
effects model. ICC, intraclass correlation coefficient; CI, confidence interval; VANS, VA
Neuropathy Scale; TCT, telehealth care technician.
The overall ICC for the VANS across all scenarios was 0.89
(95% CI: 0.81 to 0.94). The ICC for only in-person encounters
(A+B) was 0.91 (95% CI: 0.81 to 0.95). For telemedicine
encounters (C+D+E) the ICC was 0.86 (95% CI: 0.75 to
0.92). The ICC for telemedicine encounters using telehealth
care technicians (D+E) was 0.85 (95% CI: 0.71–0.93). Using a
separate mixed effects model with both the in-person examiner
and the remote grader as the fixed effects did not materially
change the results. Table 4 summarizes the ICCs across the
various scenarios. Figure 5 shows the average VANS score
by scenario.
Performing a contrast of in-person (A+B) vs. remote
(C+D+E) VANS grading for the cohort shows in-person
grading to have a statistically significant higher average score
of 1.33 points (95% CI: 0.52 to 2.15). A similar difference
of 1.28 (95% CI: 0.38 to 2.18) was found when comparing
in-person (A+B) vs. remote with telehealth care technician
exam (D+E) grading. A contrast of remote grading with
an in-person neurologist (C) vs. telehealth care technician
(D+E) shows no association between score and in-person
provider type (0.16 lower with TCT; 95% CI: −1.27 to
0.95). Table 5 summarizes the grading score contrasts across
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FIGURE 5 | Average VANS score by scenario. The graph depicts the average
VANS score by scenario with 95% confidence intervals. From left to right the
mean VANS scores were as follows: A = 8.3; B = 9.5; C = 7.5; D = 6.5; E =
8.8. Please see Table 1 for a description of the scenarios A–E. VANS, VA
Neuropathy Scale.
TABLE 5 | Comparison of VANS scores by scenario.
Scenario comparisons Polyneuropathy disease category
All No PN PN-F PN+F
In-Person vs. Remote 1.33* 0.17 1.90* 1.78
(A+B vs. C+D+E) (0.52–2.15) (−0.63–0.97) (0.53–3.27) (−0.05–3.61)
In-Person vs. TCT Remote 1.28* 0.22 1.71* 1.85
(A+B vs. D+E) (0.38–2.18) (−0.65–1.09) (0.19–3.23) (−0.18–3.87)
Neurologist vs. Technician
(remote exams only)
−0.16 0.16 −0.58 0.20
(C vs. D+E) (−1.27–0.95)(−0.95–1.27)(−2.43–1.26)(−2.25–2.66)
The table displays differences in scores (with 95% confidence intervals) based on post-
regression contrasts of the mixed effects model. The first column describes the scenario
groupings (see Table 1 for scenario descriptions). Column 2 displays the results for the
entire cohort, while columns 3–5 display the results for the corresponding polyneuropathy
disease category. Scores are positive when the first scenario grouping is higher than the
second. *P-value < 0.05; VANS, VA Neuropathy Scale; TCT, telehealth care technician;
PN, polyneuropathy; PN-F, polyneuropathy without falls; PN+F, polyneuropathy with falls.
scenarios, stratified by PN disease category. Of note, participants
without PN showed no difference in score in any of the
aforementioned comparisons. In addition, there was no
difference in score in any PN disease category strata when
comparing neurologist vs. telehealth care technician exams for
remote grading scenarios.
In-person “intra-rater” exam agreement was Spearman rho =
0.95 (n = 27 participants). There was a statistically significant
difference in score distribution between the (higher) in-person
graded exam and the remote graded exam on the same
participant with the same in-person neurologist (Wilcoxon z
= 2.2, P-value = 0.03). Remote “intra-rater” exam agreement
was Spearman rho = 0.90 (n = 28). There was not a
statistically significant difference in score distribution between
the neurology-presented exam and the TCT-presented exam
on the same participant with the same remote tele-neurologist
(Wilcoxon z =−1.1, P-value= 0.29).
DISCUSSION
Development of the VA Neuropathy Scale
(VANS)
We created the VA Neuropathy Scale (VANS) to help
neurologists evaluate and manage PN via telemedicine. The
VANS was our solution to the impracticality of training non-
physician technicians to perform comprehensive neurological
exams at each community site. For the tele-PN clinics in our VA
region, the VANS has shown to be a promising clinical exam that
is easy for technicians to learn and takes only 6min to perform.
In addition, we felt that no existing PN assessment could be
used in its original form for our telemedicine context. Previous
papers have noted that PN assessments with lengthy scoring
systems and sophisticated ancillary testing for a pre-specified
disease etiology (e.g., inflammatory neuropathies, diabetic large-
fiber neuropathy) limit their utility in most clinical contexts
(18, 22) These limitations are amplified with telemedicine.
Therefore, we modified exam elements from existing, validated
assessments (summarized inTables 2, 3) to improve telemedicine
usability while still upholding the demonstrated strengths of the
underlying assessments.
One theoretical strength of the VANS is that it detects
subtle PN findings regardless of etiology. The VANS includes
sensitive exam elements for both large-fiber (e.g., vibration) and
small-fiber (e.g., pinprick) PN. While reduced ankle reflexes
are the most sensitive marker of PN, their specificity and the
ability of novice trainees to elicit reflexes accurately are low
(19, 23). The mTCNS similarly excludes ankle reflexes and
strength testing while maintaining the highest sensitivity of 7
PN scales in Zilliox et al.’s review (17, 18). In the place of
ankle reflexes or confrontational strength testing, difficulty with
heel walk is a common and early distal motor weakness sign
in patients with PN due to weakness of the tibialis anterior.
Another theoretical strength of the VANS is its potential to
monitor disease progression by noting a change in severity (e.g.,
gradations of impairment) or spread (e.g., to more proximal
regions or different fiber types) of sensory impairment. We
adapted the pinprick testing from the UENS, which was a
superior feature in detecting small-fiber neuropathy (16). The
addition of knee reflexes and position sense with the Romberg
heightens the VANS specificity (19).
Unlike other PN scoring systems, the VANS also incorporates
tests for balance, mobility, and skin integrity to capture
important vulnerabilities in more severe PN cases that warrant
further intervention through physical therapy or podiatry. These
common neurologic exam components can be performed easily
in clinic, while providing indicators of functional status, similar
to more structured tests such as the Dynamic Balance Test, the
Functional Reach Test, and the Timed Up and Go Test (24).
Concordance and Reliability Testing of the
VA Neuropathy Scale (VANS)
The VANS is a promising scale that has good agreement with
the medical record-derived, in-person evaluation of PN. Based
on a cutoff of >2 points in this pilot study, the VANS has a
high sensitivity (98%) and specificity (91%) for diagnosing PN.
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This result is on par with the validated instruments from which
it was constructed (18). As we expected, average VANS scores
increased across the PN disease categories: 0.95 for no PN, 8.66
for PN-F, and 16.53 for PN+F. While the primary outcome
of this study was not to demarcate or declare disease severity,
finding higher VANS scores in those with falls adds a modicum
of criterion-related validity.
There was a statistically significant, but clinically equivocal,
association between the score and mode of evaluation.
Specifically, in-person exams had slightly higher scores
(1.33 points) than remote exams. One plausible explanation is
that remote exams may miss subtle PN signs, especially since
the point difference was concentrated in the PN-F category.
However, this difference did not impact the concordance of
identifying the absence or presence of PN. The type of examiner
in the remote scenarios did not impact the VANS score either.
Further, the VANS demonstrates excellent reliability,
regardless of whether the exam is graded in-person or remotely,
or whether it is performed by a neurologist or a telehealth
care technician (TCT). The agreement among telemedicine
encounters (ICC = 0.86) is nearly as high as the agreement
among our gold standard in-person neurology encounters
(ICC = 0.91). Interrater reliability (ICC = 0.89 across all 5
scenarios) is nearly as high as the intra-rater reliability (rho =
0.90–0.95). Taken together, these findings suggest that the VANS
could be a “standardized” PN score across clinicians, not just a
clinician-dependent score.
Limitations
For our study, we attempted to oversample participants with
PN-F to better define the cutoff score for PN. We had fewer
participants with PN+F, and we would need a larger sample to
confidently speak about the ability of the VANS to classify PN
severity. Evaluating participants over time would also strengthen
our conclusions about the reliability and validity of using VANS
to longitudinally track disease progression.
Selecting a “gold standard” for PN presence and severity is
challenging given known shortcomings of ancillary tests. For
example, in our practice, we do not routinely perform autonomic
tests or nerve biopsies to delineate small-fiber neuropathy.
Moreover, the sensitivities of these specialized procedures are
low (25). The variable completion, timing, and method of nerve
conduction studies (NCS) in this cohort made electrodiagnostics
suboptimal for comparison to the VANS. Here, we more broadly
recruited and classified previous neurology patients based on
symptoms and signs of PN as is custom in clinical practice
(7, 23). We believe this to be a fair approach. We chose to use
the medical record-derived diagnosis and the expert scoring of
in-person board-certified neurologists as our gold standards for
concordance and reliability testing. We plan to systematically
conduct nerve conduction studies in future investigations and
compare those results to the scores on the VANS.
Finally, the VANS is the standard assessment of our tele-PN
clinic in the GLA VA, but we do add additional examination
tests to rule out PN mimics or further evaluate co-existing
conditions when needed. As an example, we supervise more
detailed pinprick testing of the hand and instruct provocative
maneuvers in the case of carpal tunnel syndrome, or we add
a straight leg raise for radiculopathy or quick leg raise for
myelopathic tone. The VANS is intended to be a focused, remote
PN exam in those patients for whom there is a significant pre-
test probability of PN and does not replace a comprehensive
neurological exam.
CONCLUSIONS
The VA Neuropathy Scale (VANS) is a promising clinical
assessment tool for diagnosing andmonitoring the severity of PN
in telemedicine settings. Rooted in existing PN instruments, the
VANS has considerable face validity. This pilot study indicates
early support for acceptable concordance and reliability of
the VANS with in-person examinations. The VANS produces
similar scores regardless of whether the exam is performed by a
neurologist or technician or whether it is graded in-person or via
telemedicine. We submit the VANS as a novel tool to augment
neuromuscular evaluations via telemedicine.
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